



田辺三菱製薬

Development Pipeline & Global Acceleration

November 4th 2008
FY2008 Second Quarter
Business Results Briefing
Keidanren Kaikan

Ken-ichi Yanagisawa
Member of the Board of Directors
Managing Executive Officer
Development Division


1. Development Pipeline Status
2. Key Development Projects
3. Other Development Topics

1. Development Pipeline Status [Domestic]

Changes since May 7, 2008



田辺三菱製薬




1. Development Pipeline Status

[Overseas] In-house developments, licensed products



Changes from May 7, 2008

 : stage up




* In preparation to file

2. Key Development Projects



田辺三菱製薬




2. Key Development Projects

Chronic Kidney Disease (CKD): US/EU Development



田辺三菱製薬



2. Key Development Projects

CTA018 (Licensed from Cytochroma, Canada)



【Indication】

Secondary Hyperparathyroidism (SHPT) in patients with CKD

【Stage】

Phase 2

【License】

Exclusive license to develop, and distribute CTA018 in the US and Asia, including Japan


【Chronic Kidney Disease Pipeline】

CTA018 is our 3rd product, following MCI-196 for hyperphosphatemia and MP-146 for CKD

【Commercialization Platform in the US】


Utilize Cytochroma's research, development and marketing know-how based on its broad experience and achievements

Development Projects for Renal Disease (CKD)



2. Key Development Projects

(MP-513, TA-7284); Development for Diabetic



Diversify into drugs for obesity & diabetic complications


Total Care Strategy:

From Diabetes to Kidney Disease




Pursue total disease care with DM as the key disease

- From metabolic risk (obesity, hyperlipidemia) to complications (kidney damage, dialysis)
- Expand discovery research multilaterally from hypoglycemia to vascular and kidney damage drugs



- Develop diabetes pipeline into blockbusters
- Overseas: licensing, co-development, co-marketing



- Obtain earlier approval for the 3 renal products
- Establish and enhance our own sales operations



**Bolster alliances to accelerate strategy
(development, marketing)**




2. Key Development Projects


(MP-424, Telaprevir): Development for HCV disease




PROVE 2 : SVR24 for patients with Genotype 1



Development schedule of Telaprevir (MP-424/VX-950)




2. Key Development Projects Remicade – LCM



Development strategy in RA treatment

Development projects (Remicade, CNTO148, MP-435)



3. Development Project Topics

Multiple Sclerosis (FTY720, T-0047)



FTY720

【 Development stage 】

- Licensed to Novartis Pharma AG, P3
- Co-development in Japan, P2

【 Generic name 】 Fingolimod

【 Mechanism of action 】 S1PR agonist

Suppression of lymphocyte emigration from secondary lymphoid tissue and thymic medulla to thymus and blood vessels.
(first in class)

T-0047

【 Development stage 】

- Licensed to GSK, P2 overseas

【 Generic name 】 Finategrast

【 Mechanism of action 】 $\alpha 4$ antagonist

Suppression of tissue invasion by lymphocytes
(oral, first in class)

Extension of Overseas P2 study (3 years)

FTY720 starting dose	1.25mg	5mg
Relapse Free (%)	68%	73%
Free of active brain lesions (%)	89%	

Filing planned by end 2009 in US & EU
(Press release from Novartis, April 2008)

Cautionary Statement

Statements contained in this presentation are based on a number of assumptions and beliefs in light of information currently available to the management of the company and is subject to significant risks and uncertainties.